UK Public Sector Contracts & Tenders

Genomics England is a company wholly owned and funded by the Department for Health & Social Care. Our vision is a world where everyone benefits from genomic healthcare​. Where genomic data and research are translated rapidly into clinical interpretations, insights, and actions, driving better patient outcomes and lower healthcare costs.  To capitalise on the opportunities within the genomic healthcare sector, and to support the delivery of the government's strategy over the next several years, Genomics England will be developing its services to increase its value offering and keep pace within rapidly growing biotech and life science sectors. Delivering our aims will involve multiple projects and programmes focused on making improvements in different areas. Genomics England's internal expertise will not always be sufficient to realise the required outcomes therefore Genomics England will draw on external partners with the necessary expertise and capacity to support delivery by establishing a framework of partners to supply the following types of services across Lots: Lot 1 a Design and Research Services - onshore Lot 1 b Design and Research Services - offshore Lot 2 a Data services - onshore Lor 2 b Data services - offshore Lot 3 a Bioengineering services - onshore Lot 3 b Bioengineering services - offshore Lot 4 a Engineering services - onshore Lot 4 b Engineering Services - offshore Lot 5 a IT strategy and architecture services - onshore Lot 5 b IT strategy and architecture services - offshore Lot 6 a Management services - onshore Lot 6 b Management Services - offshore Lot 7 a Additional services - onshore Lot 7 b Additional services - offshore Lot 8 Service Integrators Across Lots 1 - 7, suppliers may bid for multiple Lots and may provide a tender for onshore or offshore or both. This Contract Notice is issued to notify all interested potential suppliers of a procurement to establish a framework agreement in line with Regulation 33 of the Public Contracts Regulations 2015. The framework has a maximum value of.£50,000,000. The Authority will enter into 2 year framework agreements with successful Tenderers, with the potential for extension period(s). The maximum value over the initial 2 years is £25,000,000. The framework will encompass Research and Healthcare Resource providers to deliver technology outcome-based projects. The framework will have multiple suppliers and have a number of different Lots. Suppliers will be able to bid for one or multiple Lots either as a single entity or in collaboration with other organisations. Interested suppliers are invited to view more information regarding the opportunity and download the tender documents. You may need to register on Bravo if you have not already done so: https://public.bravosolution.co.uk/genomicsengland/web/login.html . Once registered, please search for the project under code itt_2011

Genomics England is seeking to partner with an executive search firm to support our hiring of a new CIO via a targeted search and selection campaign. We anticipate this supplier will shortlist candidates, arrange interviews, and manage the offer process. To express interest in this opportunity and access the tender documents, please register at https://genomicsengland.bravosolution.co.uk/ and search for project_888.

Genomics England is currently exploring the option of introducing to its technical infrastructure a tool designed primarily for administrative purposes, where end-users will not interact with the software directly. The tool should enable administrative teams to monitor and analyse input/output (IO) activities effectively. It needs to be scalable and capable of deployment to a 5,000-core cluster. To express interest in this opportunity and access the requirement documents, please register at https://genomicsengland.bravosolution.co.uk/ and search for project_891.

Genomics England are procuring a Researcher Platform, i.e. a coherent and interoperable set of tools to access, visualise, and analyse research data. Continuing our alignment with the government “cloud-first” strategy, the Researcher Platform will leverage the underlying cloud infrastructure which is procured separately. The Researcher Platform we are seeking to procure includes specialised tools, features to promote collaboration, and scientifically focused user interfaces missing from the standard cloud provider’s toolkits. This will result in easier onboarding and adoption, better user experience, larger reach and scale-up. The procurement of the Researcher Platform is driven by Genomics England's commitment to serving Users. We aim to provide a secure, user-friendly platform that caters to varying technical abilities, ensuring that all users can effectively analyse data. This means procuring a platform with an optimal set of tools and capabilities to be leveraged to cater for these many varying needs and collaborating with a mature third-party provider that is willing to follow and implement the innovations that can improve user experience and research output. During the Contract Term the successful Supplier shall develop, Test, deploy, and support a Researcher Platform for a minimum of 600 Monthly Active Users over the Contract Term, rising to 2000 Monthly Active Users by the end of a possible five-year Contract Term. The Researcher Platform will conform with the requirements set out in the tender documentation. The expected contract signature date is April 2026, and the expected implementation period is up to 10 months. The Initial Term of the Contract from the Service Commencement Date will be three years, with the opportunity to extend by up to an additional two years, making the total possible Contract Term five years. After the Service Commencement Date, the successful Supplier will continue to develop, improve, and maintain the Researcher Platform, and provide the support services in accordance with the Contract.

Genomics England is procuring long-read whole genome sequencing services. In partnership with the NHS and other stakeholders, we are co-designing and delivering a national research study, the Generation Study, involving up to 100,000 newborns to understand the role of whole genome sequencing to achieve more timely diagnosis of rare conditions and access to early intervention, enabling faster and better care for babies born with rare childhood onset diseases. The Generation Study aims to assess the benefits, challenges, and feasibility of integrating whole genome sequencing into newborn screening to enhance the early diagnosis and treatment of rare genetic conditions. If successful, the study could establish the foundation for the world's first national newborn screening program incorporating whole genome sequencing. The study also aims to understand how, with consent, newborns' genomic and health data could be used for research to enable new diagnostic discoveries and treatments to be developed. As part of the consent to the study mothers are asked for permission to retain the baby's data and sample and link it to clinical data over the course of their life and the ability to recontact them with further research opportunities. The study will provide an invaluable dataset to researchers across industry and academia, and we have the opportunity to conduct further studies in a subset of these families to maximise the future impact to patients, researchers and the NHS. Deepening our dataset, including by introducing new modalities, is a priority for industry. To do this, we to plan to develop an enhanced longitudinal birth cohort (Babies in Focus) in a subset of participants in the next five years. This will begin with conducting long-read whole genome sequencing for at least 2,000 samples across two long-read technologies. This will help inform us of the plans for the larger funding that is being requested as part of the 2026-2030 spending review. These services will be split into two lots: Lot 1: 1,000 samples to be delivered to the supplier and sequenced between 5 January 2026 and 31 March 2026. An earlier start date may be mutually agreed by the Supplier and the Authority if implementation is completed before 5 January 2026. This lot has an estimated value of £1.4M. Lot 2: 1,000 samples to be delivered and sequenced between 1 April 2026 and 1 September 2026. An earlier start date may be mutually agreed by Supplier and the Authority, subject to the Supplier's willingness and capability, and Authority funding. This lot has an estimated value of £1.4M There is an optional extension (volume to be confirmed) of up to a total of 1,000 additional samples, valued at £1.4M. These optional extension volumes may be awarded to one or split across both lots. These optional volumes must be delivered by 1 March 2027.

This procurement is for Enterprise ITSM tooling and licences and CMDB tooling and licences, including service design, delivery/project management, implementation, and data migration support. Genomics England is exploring the Enterprise ITSM and does not currently have a configuration management data base (CMDB), which is a fundamental piece of functionality. We are seeking proposals for CMDB solutions which will be used to maintain, monitor, and obtain a better view of our environment. The solution will provide details of the machines on the network, software they're running, and expiry dates, and then link back to our contracts to provide asset numbers of kit etc. Software, licensing, and support will need to be procured to meet this project's needs.

Genomics England is aiming to return any ‘condition suspected’ findings regarding an agreed list of 200+ severe conditions for which there is an intervention available early in childhood to families in a timeframe which enables clinicians to order confirmatory tests and start therapeutic treatment. The optimal timeframe has been assessed as 14 working days, with 7 working days of this allocated to extraction and sequencing. ‘No condition suspected’ findings will be returned directly to participants and will not be subject to target turnaround times. However, as this is not known until sequencing is complete, the net impact is that all sequences should be delivered in the timelines described. The study aims to develop ‘modular’ evidence for policy makers on sequencing as in other areas. For example, separating the evidence on the performance of specific sequencing platforms to detect a particular range of genomic variation from the evidence on the impact of using screening led by the detection of particular classes of genomic variation. This mirrors the ‘technology agnostic’ approach taken by NHS England in the NHS Genomic Test Directory. To this end, Genomics England are considering a multi-supplier supply chain approach across technologies during the course of the study that enable the development of this evidence. With this approach the sequencing volumes can be delivered by multiple suppliers using a variety of technologies.

Genomics England is looking to partner with an organisation to provide a cloud-based platform for researchers to efficiently carry out analyses using the NGRL data within our secure infrastructure.